196861-33-3 Usage
General Description
2-Methoxy-5-(pyridin-4-yl)phenylboronic acid is a chemical compound that belongs to the class of boronic acids and is used in various organic synthesis reactions. It is a boronic acid derivative with a phenyl and pyridine functional group, as well as a methoxy group attached to the phenyl ring. 2-METHOXY-5-(PYRIDIN-4-YL)PHENYLBORONIC ACID is commonly used as a reagent in Suzuki-Miyaura cross-coupling reactions, which are widely used in the construction of carbon-carbon bonds in organic synthesis. It is also used in the development of pharmaceuticals and agrochemicals, as well as in the production of materials and fine chemicals. Overall, 2-Methoxy-5-(pyridin-4-yl)phenylboronic acid is an important and versatile compound with various applications in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 196861-33-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,8,6 and 1 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 196861-33:
(8*1)+(7*9)+(6*6)+(5*8)+(4*6)+(3*1)+(2*3)+(1*3)=183
183 % 10 = 3
So 196861-33-3 is a valid CAS Registry Number.
InChI:InChI=1/C12H12BNO3/c1-17-12-3-2-10(8-11(12)13(15)16)9-4-6-14-7-5-9/h2-8,15-16H,1H3
196861-33-3Relevant articles and documents
Large-scale Negishi coupling as applied to the synthesis of PDE472, an inhibitor of phosphodiesterase type 4D
Manley, Paul W.,Acemoglu, Murat,Marterer, Wolfgang,Pachinger, Werner
, p. 436 - 445 (2003)
5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole (PDE472) is a selective inhibitor of the phosphodiesterase PDE4D isoenzyme, which is a recognised drug target for the treatment of asthma. Different synthetic routes to PDE472 were investigated, and the research synthesis was optimised to prepare a phase I batch on pilot-plant scale with the focus on the elimination or minimization of inherent process risks. An important refinement of the key Negishi aryl-aryl coupling involved preforming the arylpalladium complex, which was then added to the arylzinc intermediate. Residual palladium was removed from PDE472 via crystallization of the hemi-maleate salt, which afforded drug-substance containing 2 ppm Pd.
